RE:RE:RE:RE:The Comapny Performed, Management disappointed. Super_Cycle: I appreciate your comments and I wish to offer a couple of comments on pharma innovation and the Brexit issue that you do not care about. A comment about innovation: Is it more important to customers to have a drug that is innovative than a reformulation. It comes down to making a difference in peoples lives. Our share price is telling you that you should care about it. Second, you should be concerned with Brexit. From what research I have done so far on the topic, the US market differs from the US: In the US meds need to be sold to individual doctors; in the UK the only one who needs to be sold is the government. So if something affects the government and has economic consequences to the symbiotic relationships that the UK presently with other European nations, that it is only logical to conclude that it will affect the businesses that have an investment in the UK! Just my opinion, time will tell how this Brexit unfolds.
Super_Cycle wrote: I don't care about "true innovation".
Management reaffirmed guidance and I consider this company undervalued - so the numbers are what I care about. If you don't trust management - then you must sell, why be involved with a company in which you don't trust amangement?
My impression of the Brexit question was that there was simply a misunderstanding as to the question itself. It was answered. They said that a Brexit would not impact the sale of drugs and writing of Rx's - that's actually pretty obvious.
The question on FX, agreed, it wasn't handled well. Saying "it's a wash" is not an explanation...but like I said, from a PR perspective the call was not managed well. I'm sure a LOT of thought has gone into Fx - again, you either believe in management or not.
I definitely got the sense the company is extremely frustrated with the constant comparison to Valeant. IMO these numbers should have been enough to satisfy the market, but the short term machinations of the market are beyong my comprehension.
Cheers